Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2013, Pages 132-137

  Hirai, Keita ^a,b   Hayashi, Hideki ^a   Ono, Yasuo ^b   Izumiya, Kohei ^a   Tanaka, Masaki ^a   Suzuki, Takayo ^b   Sakamoto, Tatsuichiro ^b   Itoh, Kunihiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

Author keywords

CYP2C9; CYP4F2; Japanese pediatric patients; Menaquinon 4; Vitamin K1; VKORC1; Warfarin

Indexed keywords

MENATETRENONE; VITAMIN K GROUP; WARFARIN;

ADOLESCENT; ALLELE; ARTICLE; BODY SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG SENSITIVITY; FEMALE; GENETIC ANALYSIS; HUMAN; JAPANESE; MALE; PEDIATRICS; PHARMACOLOGICAL PARAMETERS; PRESCHOOL CHILD; SCHOOL CHILD; VITAMIN BLOOD LEVEL; VKORC1 GENE; WARFARIN SENSITIVITY INDEX; WILD TYPE;

EID: 84876762867     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-078     Document Type: Article

References (40)

1. Bonduel, M. M.: Oral anticoagulation therapy in children. Thromb. Res., 118: 85-94 (2006).
2. Yoshizawa, M., Hayashi, H., Tashiro, Y., Sakawa, S., Moriwaki, H., Akimoto, T., Doi, O., Kimura, M., Kawarasaki, Y., Inoue, K. and Itoh, K.: Effect of VKORC1-1639G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb. Res., 124: 161-166 (2009).
3. Breckenridge, A., Orme, M., Wesseling, H., Lewis, R. J. and Gibbons, R.: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther., 15: 424-430 (1974).
4. Takahashi, H. and Echizen, H.: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet., 40: 587-603 (2001).
5. Kaminsky, L. S. and Zhang, Z. Y.: Human P450 metabolism of warfarin. Pharmacol. Ther., 73: 67-74 (1997).
6. Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., Milligan, P. E., Grice, G., Lenzini, P., Rettie, A. E., Aquilante, C. L., Grosso, L., Marsh, S., Langaee, T., Farnett, L. E., Voora, D., Veenstra, D. L., Glynn, R. J., Barrett, A. and McLeod, H. L.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther., 84: 326-331 (2008).
7. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J., Caldwell, M. D. and Johnson, J. A.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360: 753-764 (2009).
8. Lenzini, P., Wadelius, M., Kimmel, S., Anderson, J. L., Jorgensen, A. L., Pirmohamed, M., Caldwell, M. D., Limdi, N., Burmester, J. K., Dowd, M. B., Angchaisuksiri, P., Bass, A. R., Chen, J., Eriksson, N., Rane, A., Lindh, J. D., Carlquist, J. F., Horne, B. D., Grice, G., Milligan, P. E., Eby, C., Shin, J., Kim, H., Kurnik, D., Stein, C. M., McMillin, G., Pendleton, R. C., Berg, R. L., Deloukas, P. and Gage, B. F.: Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther., 87: 572-578 (2010).
9. McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K. and Rettie, A. E.: CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 75: 1337-1346 (2009).
10. Kikuta, Y., Kusunose, E., Kondo, T., Yamamoto, S., Kinoshita, H. and Kusunose, M.: Cloning and expression of a novel form of leukotriene B4 omega-hydroxylase from human liver. FEBS Lett., 348: 70-74 (1994).
11. Parker, R. S., Sontag, T. J., Swanson, J. E. and McCormick, C. C.: Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann. N. Y. Acad. Sci., 1031: 13-21 (2004).
12. Powell, P. K., Wolf, I., Jin, R. and Lasker, J. M.: Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther., 285: 1327-1336 (1998).
13. Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., King, C. R., Brower, A., Schmelzer, J. R., Glurich, I., Vidaillet, H. J., Yale, S. H., Qi Zhang, K., Berg, R. L. and Burmester, J. K.: CYP4F2 genetic variant alters required warfarin dose. Blood, 111: 4106-4112 (2008).
14. Borgiani, P., Ciccacci, C., Forte, V., Sirianni, E., Novelli, L., Bramanti, P. and Novelli, G.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics, 10: 261-266 (2009).
15. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., Holm, L., Lindh, J., Rane, A., Wadelius, M. and Deloukas, P.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet., 5: e1000433 (2009).
16. Cushman, M., Booth, S. L., Possidente, C. J., Davidson, K. W., Sadowski, J. A. and Bovill, E. G.: The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br. J. Haematol., 112: 572-577 (2001).
17. Karlson, B., Leijd, B. and Hellstrom, K.: On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med. Scand., 220: 347-350 (1986).
18. Kurnik, D., Lubetsky, A., Loebstein, R., Almog, S. and Halkin, H.: Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann. Pharmacother., 37: 1603-1606 (2003).
19. Wallin, R. and Hutson, S. M.: Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol. Med., 10: 299-302 (2004).
20. Okano, T., Shimomura, Y., Yamane, M., Suhara, Y., Kamao, M., Sugiura, M. and Nakagawa, K.: Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4accumulation in cerebra of mice. J. Biol. Chem., 283: 11270-11279 (2008).
21. Du Bois, D. and Du Bois, E. F.: A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition, 5: 303-311; discussion 312-303 (1989).
22. Moridani, M., Fu, L., Selby, R., Yun, F., Sukovic, T., Wong, B. and Cole, D. E.: Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin. Biochem., 39: 606-612 (2006).
23. Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K. and Kamali, F.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106: 2329-2333 (2005).
24. Cen, H. J., Zeng, W. T., Leng, X. Y., Huang, M., Chen, X., Li, J. L., Huang, Z. Y., Bi, H. C., Wang, X. D., He, Y. L., He, F., Zhou, R. N., Zheng, Q. S. and Zhao, L. Z.: CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br. J. Clin. Pharmacol., 70: 234-240 (2010).
25. Ducros, V., Pollicand, M., Laporte, F. and Favier, A.: Quantitative determination of plasma vitamin K1 by high-performance liquid chromatography coupled to isotope dilution tandem mass spectrometry. Anal. Biochem., 401: 7-14 (2010).
26. Nakamura, K., Obayashi, K., Araki, T., Aomori, T., Fujita, Y., Okada, Y., Kurabayashi, M., Hasegawa, A., Ohmori, S., Nakamura, T. and Yamamoto, K.: CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J. Clin. Pharm. Ther., 37: 481-485 (2012).
27. Singh, O., Sandanaraj, E., Subramanian, K., Lee, L. H. and Chowbay, B.: Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab. Pharmacokinet., 26: 130-136 (2011).
28. Lee, K. E., Chang, B. C., Kim, H. O., Yoon, I. K., Lee, N. R., Park, H. Y. and Gwak, H. S.: Effects of CYP4F2 Gene Polymorphisms on Warfarin Clearance and Sensitivity in Korean Patients With Mechanical Cardiac Valves. Ther. Drug Monit., 34: 275-282 (2012).
29. Nakagawa, K., Hirota, Y., Sawada, N., Yuge, N., Watanabe, M., Uchino, Y., Okuda, N., Shimomura, Y., Suhara, Y. and Okano, T.: Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature, 468: 117-121 (2010).
30. Booth, S. L., Tucker, K. L., McKeown, N. M., Davidson, K. W., Dallal, G. E. and Sadowski, J. A.: Relationships between dietary intakes and fasting plasma concentrations of fat-soluble vitamins in humans. J. Nutr., 127: 587-592 (1997).
31. Sangviroon, A., Panomvana, D., Tassaneeyakul, W. and Namchaisiri, J.: Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab. Pharmacokinet., 25: 531-538 (2010).
32. Nowak-Göttl, U., Dietrich, K., Schaffranek, D., Eldin, N. S., Yasui, Y., Geisen, C. and Mitchell, L. G.: In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood, 116: 6101-6105 (2010).
33. Takahashi, H., Ishikawa, S., Nomoto, S., Nishigaki, Y., Ando, F., Kashima, T., Kimura, S., Kanamori, M. and Echizen, H.: Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther., 68: 541-555 (2000).
34. Dingemanse, J. and van Giersbergen, P. L.: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet., 43: 1089-1115 (2004).
35. Weber, C., Schmitt, R., Birnboeck, H., Hopfgartner, G., Eggers, H., Meyer, J., van Marle, S., Viischer, H. W. and Jonkman, J. H.: Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol., 39: 703-714 (1999).
36. Spangler, M. L. and Saxena, S.: Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin. Ther., 32: 53-56 (2010).
37. Weber, C., Banken, L., Birnboeck, H. and Schulz, R.: Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol., 39: 847-854 (1999).
38. Moreau, C., Bajolle, F., Siguret, V., Lasne, D., Golmard, J. L., Elie, C., Beaune, P., Cheurfi, R., Bonnet, D. and Loriot, M. A.: Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood, 119: 861-867 (2012).
39. Kato, Y., Ichida, F., Saito, K., Watanabe, K., Hirono, K., Miyawaki, T., Yoshimura, N., Horiuchi, I., Taguchi, M. and Hashimoto, Y.: Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab. Pharmacokinet., 26: 295-299 (2011).
40. Kosaki, K., Yamaghishi, C., Sato, R., Semejima, H., Fuijita, H., Tamura, K., Maeyama, K., Yamagishi, H., Sugaya, A., Dodo, H., Tanigawara, Y. and Takahashi, T.: 1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr. Cardiol., 27: 685-688 (2006).